TABLE 1

Data Characteristics

Characteristic89Zr-anti-CD2089Zr-anti-EGFR89Zr-anti-PSMA89Zr-anti-HER2
mAbObinutuzumabCetuximabHu-J591Trastuzumab
TypeHumanizedChimericHumanizedHumanized
IgG subclassIgG1IgG1IgG1IgG1
Target expression (20)
 KidneyAbsentAbsentPresentAbsent
 LiverAbsentPresentPresentPresent
 LungAbsentAbsentAbsentPresent
 SpleenPresentAbsentAbsent*Absent
CenterAmsterdam UMC (n = 4); CHU Lille (n = 5)Amsterdam UMCMemorial Sloan Kettering Cancer CenterMemorial Sloan Kettering Cancer Center
Patient categoryNon-Hodgkin lymphomaColorectal carcinomaProstate cancerGastric cancer
Number of patients971010
Injected activity/mAb dose37 MBq/10 mg; 1,000 mg unlabeled mAb37 MBq/10 mg; 500 mg/m2 unlabeled mAb185 MBq/1.7 mg; total mass of 25 mg mAb185 MBq/3 mg; total mass of 50 mg mAb
Administration†PredosePredoseCoinjectionCoinjection
PET scan time points1 h, 72 h, 144 h after injection1 h, 72 h, 144 h after injection2–4 h, 24 h, 48–120 h, 144–168 h after injection4 h, 24 h, 48–96 h, 120–192 h after injection
Blood sample‡PlasmaPlasmaSerumSerum
Blood sampling time points5, 30, 60, 120 min; 24, 72, 144 h after injection1–2, 24, 48, 72, 144 h5, 30, 60, 120–240 min; 24, 48–120, 144–168 h after injection5, 15, 30, 60 min; 2, 24,48–96, 120–192 h after injection
ReferenceJauw et al. (16)Menke et al. (17)Pandit-Taskar et al. (18)O’Donoghue et al. (19)

  • ↵* Expression of prostate-specific membrane antigen in spleen has been reported (24).

  • ↵† Predose = 89Zr-mAb within 2 h after administration of unlabeled mAb.

  • ↵‡ Blood samples consisted of plasma or serum samples, assuming no practical difference between these assays for our purposes because mAb binding does not occur to coagulation factors (difference between plasma and serum).

  • ↵ Blood samples obtained at 24 h after injection at CHU Lille (n = 5); no 24-h sample obtained at Amsterdam UMC.

  • Coinjection = unlabeled mAb infused intravenously over 5 min followed immediately by 1 min infusion of radiolabeled mAb.